Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fuji
Chinese Patent Office
Dow
Cerilliant
Boehringer Ingelheim
Argus Health
Covington
Express Scripts

Generated: February 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OXCARBAZEPINE

« Back to Dashboard

Clinical Trials for Oxcarbazepine

Trial ID Title Status Sponsor Phase Summary
NCT00050934 Pediatric Epilepsy Study Completed Novartis Pharmaceuticals Phase 3 This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
NCT00050947 Pediatric Epilepsy Study Completed Novartis Pharmaceuticals Phase 3 This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
NCT00068770 Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated National Cancer Institute (NCI) Phase 2 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00068770 Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated Sidney Kimmel Comprehensive Cancer Center Phase 2 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00142025 Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Completed Rea Rehabilitation Centre, Georgia Phase 4 The purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma.
NCT00142025 Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Completed Centre of Chinese Medicine, Georgia Phase 4 The purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma.
NCT00145691 The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) Completed Sykehuset Innlandet HF Phase 3 We intend to conduct a phase III b trial to verify Oxcarbazepine's effect in agitation and aggression in patients with dementia. We designed the study as a randomized, double-blind, placebo-controlled multi center trial. Hundred patients will be included. The treatment period will be eight weeks, with a further follow up of four weeks. The primary outcome measure will be the reduction in aggression and agitation as measured by means of NPI-NH-subscale agitation / aggression (Neuropsychiatric Inventory, Nursing Home Version). Secondary outcomes are reduction in aggression as measured by BARS (Behavior Agitation Rating Scale)and reduction in the burden to health-care personnel as measured by NPI-NH.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Oxcarbazepine

Condition Name

Condition Name for Oxcarbazepine
Intervention Trials
Epilepsy 14
Seizures 5
Healthy 5
Bipolar Disorder 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Oxcarbazepine
Intervention Trials
Epilepsy 18
Seizures 13
Epilepsies, Partial 12
Bipolar Disorder 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Oxcarbazepine

Trials by Country

Trials by Country for Oxcarbazepine
Location Trials
United States 112
Japan 34
Mexico 15
Germany 10
Italy 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Oxcarbazepine
Location Trials
Texas 8
New York 8
Georgia 7
Florida 7
Pennsylvania 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Oxcarbazepine

Clinical Trial Phase

Clinical Trial Phase for Oxcarbazepine
Clinical Trial Phase Trials
Phase 4 18
Phase 3 9
Phase 2/Phase 3 4
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Oxcarbazepine
Clinical Trial Phase Trials
Completed 40
Recruiting 6
Terminated 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Oxcarbazepine

Sponsor Name

Sponsor Name for Oxcarbazepine
Sponsor Trials
Roxane Laboratories 5
Novartis Pharmaceuticals 5
Novartis 5
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Oxcarbazepine
Sponsor Trials
Other 48
Industry 36
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Farmers Insurance
Colorcon
Julphar
Chubb
QuintilesIMS
Cerilliant
US Department of Justice
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.